Can you provide average biomarker changes with sapropterin use?

How do biomarker changes look in patients taking sapropterin?

Sapropterin lowers blood phenylalanine levels in patients with tetrahydrobiopterin-responsive phenylketonuria. Studies show reductions of 20–30% from baseline after four weeks of treatment. The average drop is roughly 123–200 µmol/L, depending on patient age, baseline levels, and dose.

What happens to other phenylalanine-related markers when patients use sapropterin?

The drug improves phenylalanine tolerance, letting patients eat more protein. It raises blood tyrosine levels by 20–30% in some cases. Blood glutamine and serine levels also show modest rises. These changes occur alongside the main phenylalanine reduction.

Why do biomarker responses vary across patients?

Patient age, residual phenylalanine hydroxylase activity, and dose (5–20 mg/kg/day) drive most variation. Adults show smaller absolute drops than children. High-dose regimens reach 30% reductions faster, but the 10 mg/kg/day dose is more used in practice.

When does the biomarker effect appear and stabilise?

Blood phenylalanine falls within days and reaches steady values by week four. Long-term studies tracking 20–40 weeks show the gesenkte level remains stable as long as treatment continues. Patients who stop taking the plan see levels rebound to baseline within weeks.

Can sapropterin improve patient compliance with diet?

Many patients relax their protein intake under sapropterin. This increases total dietary phenylalanine tolerance by 20–50%. Compliance often rises because the strict low-phenylalanine diet becomes less burdensome.